We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03180528
Recruitment Status : Completed
First Posted : June 8, 2017
Results First Posted : January 5, 2021
Last Update Posted : June 8, 2021
National Institutes of Health (NIH)
American Skin Association
Information provided by (Responsible Party):
Kavita Sarin, Stanford University

Brief Summary:
This phase 2 trial studies how well remetinostat works in treating patients with skin basal cell cancer. Remetinostat may slow the growth of basal cell cancer cells.

Condition or disease Intervention/treatment Phase
Skin Basal Cell Carcinoma Drug: Remetinostat Phase 2

Detailed Description:


I. Overall response rate of basal cell carcinoma (BCC) in subjects at 6 weeks.


I. Suppression of GLI1 (glioma-associated oncogene) expression in treated BCCs as compared with baseline.

II. Safety assessment of Remetinostat after 6 weeks of topical treatment.


Tumors receive Remetinostat topically three times per day (TID) for 6 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed for at least 4 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Open-Label, Single-Arm Trial of the Efficacy of Topical Remetinostat on Basal Cell Carcinoma in Patients
Actual Study Start Date : July 7, 2018
Actual Primary Completion Date : July 7, 2020
Actual Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment (remetinostat)
Patients receive topical remetinostat 1% gel applied TID directly to the lesion, for 6 weeks in the absence of disease progression or unacceptable toxicity.
Drug: Remetinostat
Applied topically under bandage occlusion
Other Name: suberohydroxamic acid phenyl ester (SHAPE); SHAPE Gel; SHP 141; and 4 [[8 (hydroxyamino) 1,8 dioxooctyl]oxy] benzoic acid methyl ester

Primary Outcome Measures :
  1. Overall Response Rate [ Time Frame: At 6 weeks ]

    Overall response is defined as achieving either a complete response (CR) or a partial response (PR). Response is based on the Response Evaluation Criteria in Solid Tumors (RECIST), as follows.

    • CR = tumor lesion becomes undetectable
    • PR = ≥30% decrease in total tumor diameter
    • Overall response (OR) = CR+PR
    • Stable Disease (SD) = decrease in total tumor diameter is >0% and <30%
    • Progressive Disease (PD) = increase in total tumor diameter Exact binomial 90% confidence intervals (90%) will be computed for OR. The data are reported accord to the per protocol analysis, ie, including lesions for subjects who were <70% compliant with drug treatment. For subjects who were compliant but dropped out, data from their last study visit will be used if they contribute a biopsy. The analysis population will include the participants who have provided pre-treatment and post-treatment biopsies. The outcome is reported as the percent of tumor lesions that achieve OR, with 90% CI.

Secondary Outcome Measures :
  1. Number of Participants With a Decrease in Expression of the Hedgehog Biomarker Gene GLI1 [ Time Frame: 6 weeks ]
    The effect of topical remetinostat gel 1% on decreasing expression of Hedgehog biomarker gene GLI1 was determined using the RNeasy Fibrous Tissue Mini Kit (Qiagen, Valencia, CA), a polymerase chain reaction (PCR) test kit. The levels observed at baseline and after 6 weeks treatment were obtained. The outcome is reported as the number of subjects for whom a decrease in expression of the Hedgehog biomarker gene GLI1 was observed, a number without dispersion.

  2. Adverse Events Contributing to Treatment Discontinuation or Interruption [ Time Frame: 6 weeks ]
    Adverse events (AEs) contributing to treatment discontinuation or interruption are reported as the number of such events, a number without dispersion.

  3. Participants Who Discontinued Treatment or Had Treatment Interruption [ Time Frame: 6 weeks ]
    The number of participants who discontinued treatment or experienced treatment interruption within the first 6 weeks of treatment are reported as the number of such participants, a number without dispersion.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must have at least one BCC lesion > 1 cm (BCC > 5 mm) in non-cosmetically sensitive site(s)
  • Must be willing to apply the topical remetinostat 3 times daily for 6 weeks
  • For women of child bearing potential, a negative urine pregnancy test
  • Women of child bearing potential are expected to use an effective method of birth control while participating in the study and for 1 month after applying the last dose
  • For male subjects with female partners of childbearing potential, agreement to use adequate contraception while participating in the study and for 1 month after applying the last dose
  • Has signed and dated the current Institutional Review Board (IRB) approved informed consent document

Exclusion Criteria:

  • Taking any medication known to interact with histone deacetylase (HDAC) inhibitors, such as valproate or anticoagulants
  • Taking any medication known to affect hedgehog (HH) signaling pathway such as itraconazole
  • Within the past 6 months, has used topical or systemic therapies that might interfere with the evaluation of the study medication during the study; specifically, these include the topical use to the study tumors of:

    • Glucocorticoids
    • Retinoids either systemically or topically (eg, etretinate, isotretinoin, tazarotene, tretinoin, adapalene)
    • Alpha hydroxy acids (eg, glycolic acid, lactic acid) to > 5% of the skin
    • 5 fluorouracil or imiquimod and/or
    • Itraconazole
  • Has received treatment with systemic chemotherapy or agents known to be inhibitors of HH signaling, within 60 days to starting study medication
  • Currently receiving systemic medications that could affect BCC tumors (eg, oral retinoids) or might interact with remetinostat
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, recurrent seizure history or psychiatric illness/social situations that would limit compliance with study requirements
  • Moderate to severe immunosuppression due to disease or medication
  • Known or previous hypersensitivity to histone deacetylase inhibitor (HDACi)
  • History of congestive heart failure; cardiac arrhythmias; or other findings of ventricular dysfunction
  • History of current evidence of malabsorption or liver disease
  • Pregnancy or breast feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03180528

Layout table for location information
United States, California
Stanford University, School of Medicine
Palo Alto, California, United States, 94304
Sponsors and Collaborators
Kavita Sarin
National Institutes of Health (NIH)
American Skin Association
Layout table for investigator information
Principal Investigator: Kavita Sarin Stanford University
  Study Documents (Full-Text)

Documents provided by Kavita Sarin, Stanford University:
Informed Consent Form  [PDF] April 15, 2020

Layout table for additonal information
Responsible Party: Kavita Sarin, Principal Investigator, Stanford University
ClinicalTrials.gov Identifier: NCT03180528    
Other Study ID Numbers: IRB-40947
NCI-2017-00981 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
SKIN0037 ( Other Identifier: Stanford )
First Posted: June 8, 2017    Key Record Dates
Results First Posted: January 5, 2021
Last Update Posted: June 8, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Basal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Basal Cell
Benzoic Acid
Antifungal Agents
Anti-Infective Agents